Cargando…

Noncoding RNAs Associated with PPARs in Etiology of MAFLD as a Novel Approach for Therapeutics Targets

BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a complex disease that results from the accumulation of fat in the liver. MAFLD is directly associated with obesity, insulin resistance, diabetes, and metabolic syndrome. PPARγ ligands, including pioglitazone, are also used in the manag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazeminasab, Fatemeh, Baharlooie, Maryam, Ghaedi, Kamran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509273/ https://www.ncbi.nlm.nih.gov/pubmed/36164476 http://dx.doi.org/10.1155/2022/6161694

Ejemplares similares

Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice
por: Kazeminasab, Fatemeh, et al.
Publicado: (2021)

Pioglitazone Mediates Cardiac Progenitor Formation through Increasing ROS Levels
por: Baharlooie, Maryam, et al.
Publicado: (2022)

Hypothetical molecular interconnection between type 2 diabetes and dyslexia
por: Bülbül, Tuğba, et al.
Publicado: (2021)

Effects of A 4-Week Aerobic Exercise on Lipid Profile and Expression of LXRα in Rat Liver
por: Kazeminasab, Fatemeh, et al.
Publicado: (2017)

Noncoding RNAs as a novel approach to target retinopathy of prematurity
por: Kim, Hyunjong, et al.
Publicado: (2022)

Integrative in silico and in vitro transcriptomics analysis revealed new lncRNAs related to intrinsic apoptotic genes in colorectal cancer
por: Akbari, Fatemeh, et al.
Publicado: (2020)

Insulin-Related Liver Pathways and the Therapeutic Effects of Aerobic Training, Green Coffee, and Chlorogenic Acid Supplementation in Prediabetic Mice
por: Abdollahi, Milad, et al.
Publicado: (2022)

Noncoding RNAs: Novel Targets for Opioid Tolerance
por: Deng, Meiling, et al.
Publicado: (2023)

Metastasis-associated long noncoding RNAs in gastrointestinal cancer: Implications for novel biomarkers and therapeutic targets
por: Zhang, Fei-Fei, et al.
Publicado: (2016)

MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers
por: Barwal, Tushar Singh, et al.
Publicado: (2021)

Noncoding RNAs and Midbrain DA Neurons: Novel Molecular Mechanisms and Therapeutic Targets in Health and Disease
por: Pascale, Emilia, et al.
Publicado: (2020)

Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
por: Min, Li, et al.
Publicado: (2017)

Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets
por: Fatima, Roshan, et al.
Publicado: (2015)

Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease
por: Kato, Mitsuo
Publicado: (2018)

Potential Roles of Long Noncoding RNAs as Therapeutic Targets in Renal Fibrosis
por: Jung, Hyun Jin, et al.
Publicado: (2020)

Potential Roles of Long Noncoding RNAs as Therapeutic Targets in Organ Transplantation
por: Salehi, Saeedeh, et al.
Publicado: (2022)

Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer
por: Chen, Linjiao, et al.
Publicado: (2022)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
por: Escutia-Gutiérrez, Rebeca, et al.
Publicado: (2021)

Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets?
por: Kladi-Skandali, Athina, et al.
Publicado: (2015)

Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer
por: Son, Seung Wan, et al.
Publicado: (2021)

Role of Insulin Resistance in MAFLD
por: Sakurai, Yoshitaka, et al.
Publicado: (2021)

The Gut Microbiome and Ferroptosis in MAFLD
por: Ji, Jie, et al.
Publicado: (2023)

MAFLD: a multisystem disease
por: Pipitone, Rosaria Maria, et al.
Publicado: (2023)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

MAFLD and Celiac Disease in Children
por: Scapaticci, Serena, et al.
Publicado: (2023)

Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects
por: Xiao, Zhangang, et al.
Publicado: (2018)

Role of Long Noncoding RNAs in Parkinson's Disease: Putative Biomarkers and Therapeutic Targets
por: Lv, Qiankun, et al.
Publicado: (2020)

Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma
por: Shen, Haiyan, et al.
Publicado: (2021)

The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets
por: Liu, Jinxin, et al.
Publicado: (2022)

PPARγ as a Novel Therapeutic Target in Lung Cancer
por: Reddy, Aravind T., et al.
Publicado: (2016)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

Long noncoding RNAs (lncRNAs) in human lymphomas
por: Gholami, Ali, et al.
Publicado: (2021)

Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD
por: Li, Xun, et al.
Publicado: (2021)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

Screening for MAFLD: who, when and how?
por: Pal, Shreya C., et al.
Publicado: (2023)

Long Noncoding RNAs as Diagnostic and Therapeutic Targets in Type 2 Diabetes and Related Complications
por: Leti, Fatjon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f4qangbhfnd8jbqsl7867solkj